Skip to content

Study · Not a test of the peptide alone · 2025

8 results

Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy.

Dhanapalaratnam R, Issar T, Poynten AM, Milner KL, Kwai NCG, Krishnan AV

Journal of neurophysiology25 Nov 2024Cited by 14 (Europe PMC)

PMID39584713 (opens in a new tab)DOI10.1152/jn.00228.2024 (opens in a new tab)PepBankPUB-39584713
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

Diabetic peripheral neuropathy (DPN) affects approximately half of the 500 million people with type 2 diabetes worldwide. Previous studies have suggested that glucagon-like peptide-1 (GLP-1) receptors in the peripheral nervous system may be a suitable target for DPN treatment. Fourteen participants were consecutively recruited after being prescribed either semaglutide or dulaglutide as part of standard clinical care for type 2 diabetes. Participants underwent clinical assessment, nerve conduction studies, and axonal excitability assessment at baseline and at 3 mo following commencement of GLP-1 receptor agonist (GLP-1RA) therapy. These data were combined with 10 participants who had previously received exenatide therapy, and mathematical modeling of excitability data was undertaken. Clinical neuropathy scores improved at 3 mo following commencement of GLP-1 (baseline TNS 3.7 ± 4.5, posttreatment TNS 2.3 ± 3.4, P = 0.005). Nerve conduction studies demonstrated an improvement in sural amplitude at 3 mo (baseline 11.9 ± 8.5 μV, posttreatment 14.2 ± 9.2 μV; P = 0.013). Axonal excitability studies revealed changes consistent with improvements in Na+/K+-ATPase pump function and Na+ permeability, and this was supported by mathematical modeling. GLP-1RA therapy improves clinical and neurophysiological outcomes in DPN. Treatment with GLP-1RA may reverse axonal dysfunction by improving Na+/K+-ATPase pump function.NEW & NOTEWORTHY Diabetic peripheral neuropathy is known to be relentlessly progressive and irreversible. Prospective studies in 24 participants with diabetic peripheral neuropathy (DPN) treated with glucagon-like peptide-1 receptor agonists (GLP-1RA) demonstrated improvements in clinical neuropathy scores, nerve conduction studies, and axonal excitability recordings. Analysis of axonal excitability recordings revealed the mechanism for GLP-1RA improvement in DPN were changed consistent with improvements in Na+/K+-ATPase pump function, and this was supported by mathematical modeling.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In participants with diabetic neuropathy, pooled GLP-1RA treatment was linked to lower neuropathy scores at follow-up versus baseline.

    In plain wordsIn participants with diabetic neuropathy, pooled GLP-1RA treatment including dulaglutide was linked to lower neuropathy scores than baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseClinical neuropathy score
    Study

    n = 24

    Comparator
    Baseline
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    TNS
    3.7 score
    baseline
    TNS
    2.3 score
    3 mo

    Source sentences

    Summary
    Clinical neuropathy scores improved at 3 mo following commencement of GLP-1 (baseline TNS 3.7 ± 4.5, posttreatment TNS 2.3 ± 3.4, P = 0.005).
    3 context sentences
    Summary · context
    Fourteen participants were consecutively recruited after being prescribed either semaglutide or dulaglutide as part of standard clinical care for type 2 diabetes.
    Summary · context
    Participants underwent clinical assessment, nerve conduction studies, and axonal excitability assessment at baseline and at 3 mo following commencement of GLP-1 receptor agonist (GLP-1RA) therapy.
    Summary · context
    These data were combined with 10 participants who had previously received exenatide therapy, and mathematical modeling of excitability data was undertaken.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In participants with diabetic neuropathy, pooled GLP-1RA treatment was linked to lower neuropathy scores at follow-up versus baseline.

    In plain wordsIn participants with diabetic neuropathy, pooled GLP-1RA treatment including semaglutide was linked to lower neuropathy scores than baseline.

    Peptide
    Semaglutide
    Outcome
    DecreaseClinical neuropathy score
    Study

    n = 24

    Comparator
    Baseline
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    TNS
    3.7 score
    baseline
    TNS
    2.3 score
    3 mo

    Source sentences

    Summary
    Clinical neuropathy scores improved at 3 mo following commencement of GLP-1 (baseline TNS 3.7 ± 4.5, posttreatment TNS 2.3 ± 3.4, P = 0.005).
    3 context sentences
    Summary · context
    Fourteen participants were consecutively recruited after being prescribed either semaglutide or dulaglutide as part of standard clinical care for type 2 diabetes.
    Summary · context
    Participants underwent clinical assessment, nerve conduction studies, and axonal excitability assessment at baseline and at 3 mo following commencement of GLP-1 receptor agonist (GLP-1RA) therapy.
    Summary · context
    These data were combined with 10 participants who had previously received exenatide therapy, and mathematical modeling of excitability data was undertaken.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome

    In participants with diabetic neuropathy, pooled GLP-1RA treatment was linked to increased sural amplitude versus baseline.

    In plain wordsIn participants with diabetic neuropathy, pooled GLP-1RA treatment including dulaglutide was linked to greater sural nerve signals than baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseSural amplitude
    Study

    n = 24

    Comparator
    Baseline
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    Sural amplitude
    11.9 μV
    baseline
    Sural amplitude
    14.2 μV
    3 mo

    Source sentences

    Summary
    Nerve conduction studies demonstrated an improvement in sural amplitude at 3 mo (baseline 11.9 ± 8.5 μV, posttreatment 14.2 ± 9.2 μV; P = 0.013).
    3 context sentences
    Summary · context
    Fourteen participants were consecutively recruited after being prescribed either semaglutide or dulaglutide as part of standard clinical care for type 2 diabetes.
    Summary · context
    Participants underwent clinical assessment, nerve conduction studies, and axonal excitability assessment at baseline and at 3 mo following commencement of GLP-1 receptor agonist (GLP-1RA) therapy.
    Summary · context
    These data were combined with 10 participants who had previously received exenatide therapy, and mathematical modeling of excitability data was undertaken.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 04HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In participants with diabetic neuropathy, pooled GLP-1RA treatment was linked to increased sural amplitude versus baseline.

    In plain wordsIn participants with diabetic neuropathy, pooled GLP-1RA treatment including semaglutide was linked to greater sural nerve signals than baseline.

    Peptide
    Semaglutide
    Outcome
    IncreaseSural amplitude
    Study

    n = 24

    Comparator
    Baseline
    Outcome group
    Neuroprotection · Nervous system and cognition

    Measurements

    Sural amplitude
    11.9 μV
    baseline
    Sural amplitude
    14.2 μV
    3 mo

    Source sentences

    Summary
    Nerve conduction studies demonstrated an improvement in sural amplitude at 3 mo (baseline 11.9 ± 8.5 μV, posttreatment 14.2 ± 9.2 μV; P = 0.013).
    3 context sentences
    Summary · context
    Fourteen participants were consecutively recruited after being prescribed either semaglutide or dulaglutide as part of standard clinical care for type 2 diabetes.
    Summary · context
    Participants underwent clinical assessment, nerve conduction studies, and axonal excitability assessment at baseline and at 3 mo following commencement of GLP-1 receptor agonist (GLP-1RA) therapy.
    Summary · context
    These data were combined with 10 participants who had previously received exenatide therapy, and mathematical modeling of excitability data was undertaken.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism

    In participants with diabetic neuropathy, pooled GLP-1RA treatment was linked to excitability changes consistent with improved sodium-potassium pump function.

    In plain wordsIn participants with diabetic neuropathy, pooled treatment including dulaglutide was linked to nerve changes consistent with improved sodium-potassium pump function.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedAxonal excitability consistent with improved pump function
    Study

    n = 24

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Axonal excitability studies revealed changes consistent with improvements in Na+/K+-ATPase pump function and Na+ permeability, and this was supported by mathematical modeling.
    3 context sentences
    Summary · context
    Fourteen participants were consecutively recruited after being prescribed either semaglutide or dulaglutide as part of standard clinical care for type 2 diabetes.
    Summary · context
    Participants underwent clinical assessment, nerve conduction studies, and axonal excitability assessment at baseline and at 3 mo following commencement of GLP-1 receptor agonist (GLP-1RA) therapy.
    Summary · context
    These data were combined with 10 participants who had previously received exenatide therapy, and mathematical modeling of excitability data was undertaken.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  6. 06HumanNot a test of Semaglutide aloneObservational studyMechanism

    In participants with diabetic neuropathy, pooled GLP-1RA treatment was linked to excitability changes consistent with improved sodium-potassium pump function.

    In plain wordsIn participants with diabetic neuropathy, pooled treatment including semaglutide was linked to nerve changes consistent with improved sodium-potassium pump function.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedAxonal excitability consistent with improved pump function
    Study

    n = 24

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Axonal excitability studies revealed changes consistent with improvements in Na+/K+-ATPase pump function and Na+ permeability, and this was supported by mathematical modeling.
    3 context sentences
    Summary · context
    Fourteen participants were consecutively recruited after being prescribed either semaglutide or dulaglutide as part of standard clinical care for type 2 diabetes.
    Summary · context
    Participants underwent clinical assessment, nerve conduction studies, and axonal excitability assessment at baseline and at 3 mo following commencement of GLP-1 receptor agonist (GLP-1RA) therapy.
    Summary · context
    These data were combined with 10 participants who had previously received exenatide therapy, and mathematical modeling of excitability data was undertaken.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism

    In participants with diabetic neuropathy, pooled GLP-1RA treatment was linked to excitability changes consistent with improved sodium permeability.

    In plain wordsIn participants with diabetic neuropathy, pooled treatment including dulaglutide was linked to nerve changes consistent with improved sodium permeability.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedAxonal excitability consistent with improved sodium permeability
    Study

    n = 24

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Axonal excitability studies revealed changes consistent with improvements in Na+/K+-ATPase pump function and Na+ permeability, and this was supported by mathematical modeling.
    3 context sentences
    Summary · context
    Fourteen participants were consecutively recruited after being prescribed either semaglutide or dulaglutide as part of standard clinical care for type 2 diabetes.
    Summary · context
    Participants underwent clinical assessment, nerve conduction studies, and axonal excitability assessment at baseline and at 3 mo following commencement of GLP-1 receptor agonist (GLP-1RA) therapy.
    Summary · context
    These data were combined with 10 participants who had previously received exenatide therapy, and mathematical modeling of excitability data was undertaken.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  8. 08HumanNot a test of Semaglutide aloneObservational studyMechanism

    In participants with diabetic neuropathy, pooled GLP-1RA treatment was linked to excitability changes consistent with improved sodium permeability.

    In plain wordsIn participants with diabetic neuropathy, pooled treatment including semaglutide was linked to nerve changes consistent with improved sodium permeability.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedAxonal excitability consistent with improved sodium permeability
    Study

    n = 24

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Axonal excitability studies revealed changes consistent with improvements in Na+/K+-ATPase pump function and Na+ permeability, and this was supported by mathematical modeling.
    3 context sentences
    Summary · context
    Fourteen participants were consecutively recruited after being prescribed either semaglutide or dulaglutide as part of standard clinical care for type 2 diabetes.
    Summary · context
    Participants underwent clinical assessment, nerve conduction studies, and axonal excitability assessment at baseline and at 3 mo following commencement of GLP-1 receptor agonist (GLP-1RA) therapy.
    Summary · context
    These data were combined with 10 participants who had previously received exenatide therapy, and mathematical modeling of excitability data was undertaken.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.